Related Experiment Video

Updated: Jun 6, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Proteomic approaches for investigation of therapy resistance in cancer

Hermann Lage1

  • 1Institute of Pathology, Charité Campus Mitte, Berlin, Germany. hermann.lage@charite.de.

Proteomics. Clinical Applications
|December 8, 2010
PubMed

Insights

Understanding anticancer therapy resistance is crucial for cancer patient management. Proteomics offers potential for identifying resistance factors, but clinical applications remain limited.

Area of Science:

  • Oncology
  • Proteomics
  • Molecular Biology

Background:

  • Therapy resistance, particularly multidrug resistance, is a significant challenge in cancer treatment.
  • Identified mechanisms include drug efflux pumps, altered cell death pathways, and target molecule repair.
  • These mechanisms form a complex network contributing to individual therapy-resistant phenotypes.

Purpose of the Study:

  • To review proteomic data related to anticancer therapy resistance.
  • To discuss the potential of proteomics in predicting treatment response and tailoring therapy.
  • To explore future perspectives for utilizing proteomic findings in clinical oncology.

Main Methods:

  • Review of existing literature on proteomic techniques and therapy resistance.
  • Analysis of proteomic data from drug-resistant cell models and cancerous tissues.
  • Discussion of identified protein factors and expression profiles associated with resistance.

Main Results:

  • Proteomic techniques have identified numerous factors and protein signatures linked to anticancer therapy resistance.
  • Despite progress, the functional roles and clinical impact of these proteomic findings are not yet fully understood.
  • Current proteomic data has not yet led to improved diagnostic tests or chemosensitizers.

Conclusions:

  • A deeper understanding of the multifactorial resistance network is needed for personalized cancer therapy.
  • Proteomics holds promise for identifying novel biomarkers for predicting treatment response.
  • Further research is required to translate proteomic discoveries into clinically applicable tools for cancer patients.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Proteomics01:33

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...